AllPennyStocks.com This Biotech Found Mid-Week Success Following Analyst Upgrade

This Biotech Found Mid-Week Success Following Analyst Upgrade

This Biotech Found Mid-Week Success Following Analyst Upgrade By: Dylan Sikes – AllPennyStocks.com News

Wednesday, May 7, 2025

A biotech company based out of Massachusetts found a tremendous amount of success on Wednesday after Leerink Partners upgraded the stock from market perform to outperform, raising their price target for the stock from $4 to $10.

Traders wasted no time buying up shares of Amylyx Pharmaceuticals Inc. (Nasdaq:AMLX), pushing the small cap to close up at $4.87/share (+4.73%) on the day. This doesn’t come at too much of a surprise given the bullish price target versus yesterday’s close at just $4.65.

This move was a strong continuation of the success this stock has had over the last month.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.


Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Everyone Chases the Chips, This Microcap Went for the Memory
This Microcap Wants to 3D Print Your Peptides
Graphite Microcap Soars on All-Cash Buyout at 71% Premium
Most Popular
{{ index + 1 }}


Back to Top